$IRD
Opus Genetics, Inc. Stock $ird

$ird Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000114036119014413 Filed on August 07, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.150M	$1.340M	$1.570M
YoY Change	-36.11%	-14.65%	-9.77%
% of Gross Profit
Research & Development	$1.131M	$1.648M	$3.430M
YoY Change	-60.82%	-51.94%	35.04%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K	$20.00K
YoY Change	0.0%	-50.0%	100.0%
% of Gross Profit
Operating Expenses	$2.281M	$2.988M	$5.001M
YoY Change	-51.31%	-40.25%	16.75%
Operating Profit	-$2.281M	-$2.988M	-$5.001M
YoY Change	-51.31%	-40.25%	16.75%
Interest Expense	$320.0K	$520.0K	$1.160M
YoY Change	-149.23%	-55.17%	-77.82%
% of Operating Profit
Other Income/Expense, Net	$321.4K	$524.1K	$1.163M
YoY Change	-149.07%	-54.94%	-77.76%
Pretax Income	-$1.959M	-$2.464M	-$3.838M
YoY Change	-63.3%	-35.8%	-504.03%
Income Tax
% Of Pretax Income
Net Earnings	-$1.959M	-$2.464M	-$3.838M
YoY Change	-63.3%	-35.8%	-505.28%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.960M	-$2.460M	-$5.818M
COMMON SHARES
Basic Shares Outstanding	4.019M	4.019M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.91M	$16.26M	$16.74M
YoY Change	10.66%	-2.87%	-37.49%
Cash & Equivalents	$7.932M	$7.310M	$5.094M
Short-Term Investments	$5.980M	$8.950M	$11.65M
Other Short-Term Assets	$606.4K	$662.1K	$1.370M
YoY Change	-4.39%	-51.67%	14.17%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.64M	$17.29M	$18.11M
YoY Change	6.67%	-4.51%	-35.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$85.30K	$94.69K	$100.0K
YoY Change	-30.92%	-5.32%	11.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$30.00K	$30.00K	$30.00K
YoY Change	0.0%	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$344.9K	$384.0K	$130.0K
YoY Change	123.59%	195.4%	18.18%
TOTAL ASSETS
Total Short-Term Assets	$14.64M	$17.29M	$18.11M
Total Long-Term Assets	$344.9K	$384.0K	$130.0K
Total Assets	$14.98M	$17.68M	$18.24M
YoY Change	7.97%	-3.09%	-35.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$360.0K	$950.0K	$720.0K
YoY Change	-72.31%	31.94%	41.18%
Accrued Expenses	$1.140M	$1.110M	$2.660M
YoY Change	-43.84%	-58.27%	88.65%
Deferred Revenue	$1.500M	$1.500M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.001M	$3.551M	$3.380M
YoY Change	-9.87%	5.07%	76.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$220.0K	$500.0K	$3.430M
YoY Change	-94.67%	-85.42%	-66.6%
Total Long-Term Liabilities	$220.0K	$500.0K	$3.430M
YoY Change	-94.67%	-85.42%	-66.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.001M	$3.551M	$3.380M
Total Long-Term Liabilities	$220.0K	$500.0K	$3.430M
Total Liabilities	$3.230M	$4.054M	$6.810M
YoY Change	-56.72%	-40.47%	-44.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$161.5M	-$159.5M
YoY Change	6.52%
Common Stock		$173.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.76M	$13.62M	$11.42M
YoY Change
Total Liabilities & Shareholders Equity	$14.98M	$17.68M	$18.24M
YoY Change	7.96%	-3.09%	-35.07%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$1.959M	-$2.464M	-$3.838M
YoY Change	-63.3%	-35.8%	-505.28%
Depreciation, Depletion And Amortization	$10.00K	$10.00K	$20.00K
YoY Change	0.0%	-50.0%	100.0%
Cash From Operating Activities	-$2.370M	-$1.810M	-$4.450M
YoY Change	-43.17%	-59.33%	8.54%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	$0.00
YoY Change	-100.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$3.000M	$3.000M	$3.250M
YoY Change	-18.92%	-7.69%	-132.5%
Cash From Investing Activities	$3.000M	$3.000M	$3.250M
YoY Change	-18.03%	-7.69%	-132.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-2.370M	-1.810M	-4.450M
Cash From Investing Activities	3.000M	3.000M	3.250M
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	630.0K	1.190M	-1.200M
YoY Change	-223.53%	-199.17%	-29.41%
FREE CASH FLOW
Cash From Operating Activities	-$2.370M	-$1.810M	-$4.450M
Capital Expenditures	$0.00	-$10.00K	$0.00
Free Cash Flow	-$2.370M	-$1.800M	-$4.450M
YoY Change	-42.62%	-59.55%	9.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001228627
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4019141
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	REXAHN PHARMACEUTICALS, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	rexn	Amortization Of Deferred Lease Incentive AmortizationOfDeferredLeaseIncentive	-6222
	rexn	Amortization Of Deferred Research And Development Contribution AmortizationOfDeferredResearchAndDevelopmentContribution	-375000
CY2019Q1	rexn	Common Stock Issuance Cost Incurred CommonStockIssuanceCostIncurred	1046172
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2464284
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5094275
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7310049
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3813847
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	147767
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	61237
	rexn	Investment Warrants Expired Weighted Average Exercise Price InvestmentWarrantsExpiredWeightedAverageExercisePrice	153.60
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	19781
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	24421
CY2019Q2	rexn	Warrant Liabilities WarrantLiabilities	366732
CY2019Q2	rexn	Warrants Exercise Price WarrantsExercisePrice	22.10
CY2019Q2	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	945829
CY2019Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	89000
CY2019Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1921489
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2444503
CY2018	rexn	Investment Warrants Fair Value Assumptions Estimated Dividend InvestmentWarrantsFairValueAssumptionsEstimatedDividend
CY2018	rexn	Investment Warrants Fair Value Assumptions Estimated Future Volatility Rate InvestmentWarrantsFairValueAssumptionsEstimatedFutureVolatilityRate	1.05
CY2018	rexn	Investment Warrants Fair Value Assumptions Trading Market Prices InvestmentWarrantsFairValueAssumptionsTradingMarketPrices	11.16
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	3152550
CY2018Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	140637
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5921210
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4782265
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.24
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.23
	rexn	Deferred Lease Expenses DeferredLeaseExpenses	-10927
CY2018Q4	rexn	Deferred Tax Assets Book Tax Differences On Assets And Liabilities DeferredTaxAssetsBookTaxDifferencesOnAssetsAndLiabilities	195000
CY2019Q2	rexn	Deferred Tax Assets Book Tax Differences On Assets And Liabilities DeferredTaxAssetsBookTaxDifferencesOnAssetsAndLiabilities	508000
	rexn	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00
	rexn	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	1
	rexn	Defined Contribution Plan Maximum Annual Contribution Per Employee Additional Percent On Deferral DefinedContributionPlanMaximumAnnualContributionPerEmployeeAdditionalPercentOnDeferral	0.5
CY2019Q2	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1568848
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3035538
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-5913141
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3838268
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-4807280
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Investment Income Interest InvestmentIncomeInterest	143209
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	67473
	us-gaap	Investment Income Interest InvestmentIncomeInterest	178035
	rexn	Investment Warrants Exercised Number InvestmentWarrantsExercisedNumber
	rexn	Investment Warrants Exercised Weighted Average Exercise Price InvestmentWarrantsExercisedWeightedAverageExercisePrice
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1163173
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2118889
	us-gaap	Operating Expenses OperatingExpenses	10887296
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	5001441
	us-gaap	Operating Expenses OperatingExpenses	6926169
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10887296
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5001441
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6926169
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	47129
	rexn	Fixed Contingent Consideration FixedContingentConsideration	3000000
	rexn	Investment Warrants Expired Number InvestmentWarrantsExpiredNumber	39683
CY2018Q4	rexn	Investment Warrants Fair Value InvestmentWarrantsFairValue	2307586
CY2019Q2	rexn	Investment Warrants Fair Value InvestmentWarrantsFairValue	366732
CY2018	rexn	Investment Warrants Fair Value Assumptions Estimated Additional Shares Issued Upon Dilutive Event InvestmentWarrantsFairValueAssumptionsEstimatedAdditionalSharesIssuedUponDilutiveEvent	0.05
	rexn	Investment Warrants Fair Value Assumptions Estimated Additional Shares Issued Upon Dilutive Event InvestmentWarrantsFairValueAssumptionsEstimatedAdditionalSharesIssuedUponDilutiveEvent	0.05
	rexn	Investment Warrants Fair Value Assumptions Estimated Dividend InvestmentWarrantsFairValueAssumptionsEstimatedDividend
	rexn	Investment Warrants Fair Value Assumptions Estimated Future Volatility Rate InvestmentWarrantsFairValueAssumptionsEstimatedFutureVolatilityRate	1.02
	rexn	Investment Warrants Fair Value Assumptions Trading Market Prices InvestmentWarrantsFairValueAssumptionsTradingMarketPrices	5.16
	rexn	Investment Warrants Issued Number InvestmentWarrantsIssuedNumber	895886
CY2019Q1	rexn	Investment Warrants Issued Number InvestmentWarrantsIssuedNumber	895886
	rexn	Investment Warrants Issued Weighted Average Exercise Price InvestmentWarrantsIssuedWeightedAverageExercisePrice	9.60
	rexn	Investment Warrants Weighted Average Remaining Contractual Term InvestmentWarrantsWeightedAverageRemainingContractualTerm	P4Y2M12D
CY2018Q1	rexn	Licensing Revenue Agreement Percent LicensingRevenueAgreementPercent	0.5
CY2019Q1	rexn	Proceeds From Issuance Of Common Stock Gross ProceedsFromIssuanceOfCommonStockGross	8600000
CY2009Q2	rexn	Research And Developement Agreement One Time Milestone Payment ResearchAndDevelopementAgreementOneTimeMilestonePayment	1000000
CY2019Q2	rexn	Research And Development Estimated Cost To Complete Contracts With Vendors ResearchAndDevelopmentEstimatedCostToCompleteContractsWithVendors	3870000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	288653
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	127653
CY2018Q4	us-gaap	Assets Assets	16042926
CY2018Q4	rexn	Warrant Liabilities WarrantLiabilities	2307586
CY2018Q4	rexn	Warrants Exercise Price WarrantsExercisePrice	37.52
	rexn	Warrants Issued WarrantsIssued	4735913
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	288653
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	127653
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	563728
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3152550
CY2019Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1920734
CY2019Q2	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1920734
CY2018Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	547519
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-26504
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	56019
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	709117
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	268240
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17836
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7179
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	165267656
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	173110047
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	563728
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	267151
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	267151
CY2019Q2	us-gaap	Assets Assets	17677234
CY2018Q4	us-gaap	Assets Current AssetsCurrent	15899668
CY2019Q2	us-gaap	Assets Current AssetsCurrent	17293210
CY2019Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	8950120
CY2019Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	8950120
CY2019Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7179
CY2019Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	8942941
CY2018Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	5981520
CY2019Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	8950120
CY2019Q2	us-gaap	Billed Contract Receivables BilledContractReceivables	1500000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8899154
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8744301
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3804879
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1434252
CY2019Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.60
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1065286
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3122843
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7491126
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
	us-gaap	Revenues Revenues
CY2018Q2	us-gaap	Revenues Revenues
	us-gaap	Revenues Revenues
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4019141
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3122843
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4019141
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	312
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	402
CY2019Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1500000
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	19900
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2019Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	41184000
CY2019Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42678000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1608000
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1265000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42987000
CY2019Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44451000
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	70277
CY2018Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	34468
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	46385
CY2019Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	18506
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.02
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27188
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.45
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2018Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	682263
CY2019Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	262639
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4462196
CY2018Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1095700
CY2019Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-427483
CY2019Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2019Q2	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2019Q2	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1231816
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1500000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	12150
	us-gaap	Lease Cost LeaseCost	150079
CY2019Q2	us-gaap	Lease Cost LeaseCost	53788
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-6706
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-22308
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	96650
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9594
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1340016
CY2019Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.11
	us-gaap	Operating Lease Payments OperatingLeasePayments	120700
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	297168
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	78437
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	154961
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	63770
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	30506
CY2018Q4	us-gaap	Liabilities Liabilities	5480036
CY2019Q2	us-gaap	Liabilities Liabilities	4054128
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16042926
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17677234
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3152550
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3551200
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2307586
CY2019Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	366732
	us-gaap	Nature Of Operations NatureOfOperations	<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt 0pt 0pt 21.6pt;text-indent:-21.6pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-weight:bold;font-family:Times New Roman;font-size: 11pt"> <a name="_Hlk512345999"></a><font style="display: inline;">1.</font><font style="display: inline;;font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;">Operations and Organization</font> </p> <p style="margin:10.8pt 0pt 0pt 23.75pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;">Operations</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">Rexahn Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, is a biopharmaceutical company whose principal operations are the development of innovative treatments for cancer.  The Company had an accumulated deficit of </font><font style="display: inline;">$159,494,522</font><font style="display: inline;"> at </font><font style="display: inline;">June 30</font><font style="display: inline;">, 2019 and anticipates incurring losses through fiscal year 2019 and beyond.  The Company has not yet generated commercial revenues and has funded its operations to date through the sale of shares of its common stock and warrants, exercises of stock warrants, interest income from cash, cash equivalents and marketable securities, and proceeds from reimbursed research and development costs.  The Company believes that its cash, cash equivalents and marketable securities, will be sufficient to cover its cash flow requirements for its current activities for at least for the next 12 months from the date these financial statements were issued.  Management believes it has the capability of managing the Company’s operations within existing cash available by focusing on select research and development activities, selecting projects in conjunction with potential financings and milestones, and efficiently managing its general and administrative affairs.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;">Basis of Presentation</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission for interim financial information.  Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete financial statements.  In the opinion of the Company’s management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of </font><font style="display: inline;">June 30</font><font style="display: inline;">, 2019 and December 31, 2018 and of the results of operations, comprehensive loss</font><font style="display: inline;"> and stockholders’ equity</font><font style="display: inline;"> for the three </font><font style="display: inline;">and six </font><font style="display: inline;">months ended </font><font style="display: inline;">June 30</font><font style="display: inline;">, 2019 and 2018</font><font style="display: inline;">, and cash flows for the six months ended June 30, 2019 and 2018</font><font style="display: inline;"> have been included.  Operating results for the three </font><font style="display: inline;">and six </font><font style="display: inline;">months ended </font><font style="display: inline;">June 30</font><font style="display: inline;">, 2019 are not necessarily indicative of results that may be expected for any other interim period or the full fiscal year ending December 31, 2019. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (the “2018 Form 10-K”).  Information included in the condensed balance sheet as of December 31, 2018 has been derived from the Company’s audited financial statements for the year ended December 31, 2018 included in the 2018 Form 10-K.</font><font style="display: inline;">    </font><font style="display: inline;">The unaudited condensed financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;"></font> </p> <p style="margin:0pt;text-indent:23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <a name="_Hlk512346000"></a><font style="display: inline;font-style:italic;">Use of Estimates</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future.  Actual results may ultimately differ from these estimates.  These estimates are reviewed periodically, and as adjustments become necessary, they are reported in earnings in the period in which they become available. </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> </p> <p><font size="1"> </font></p> <p style="margin:0pt;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;"></font> </p> <p style="margin:10.8pt 0pt 0pt 23.75pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 1pt"> <font style="display: inline;font-weight:bold;font-size:1pt;background-color:yellow;"></font> </p> <p><font size="1"> </font></p> </div> </div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7653828
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6246507
	us-gaap	Net Income Loss NetIncomeLoss	-5913141
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-3838268
	us-gaap	Net Income Loss NetIncomeLoss	-4807280
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2464284
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4974155
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	524133
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2988417
	us-gaap	Operating Lease Cost OperatingLeaseCost	127407
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	266662
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130466
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	136196
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	263658
CY2019Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	147086000
CY2019Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	152421000
CY2018Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1782131
CY2019Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	623266
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	555430
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	662099
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8069
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2640391
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2640927
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3900208
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	24421
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	25015
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19781
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	368750
CY2018Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	618417
CY2019Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	370942
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	8887566
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1173847
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1033041
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6250000
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	5500
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	821590
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	362925
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112473
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94685
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1648401
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-154687242
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-159494522
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3000000
CY2019Q2	us-gaap	Revenues Revenues
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	380935
CY2018Q4	us-gaap	Security Deposit SecurityDeposit	30785
CY2019Q2	us-gaap	Security Deposit SecurityDeposit	25681
	us-gaap	Share Based Compensation ShareBasedCompensation	563728
	us-gaap	Share Based Compensation ShareBasedCompensation	288653
CY2019Q1	us-gaap	Share Price SharePrice	9.60
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	16768596
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	14969960
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	11423264
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	10562890
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	15939956
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	13623106
CY2019Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.083
CY2019Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	895834
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	464
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	12150
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7553828
	us-gaap	Use Of Estimates UseOfEstimates	<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:23.75pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;">Use of Estimates</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future.  Actual results may ultimately differ from these estimates.  These estimates are reviewed periodically, and as adjustments become necessary, they are reported in earnings in the period in which they become available. </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> </p> <p><font size="1"> </font></p> <p style="margin:0pt;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;"></font> </p> <p><font size="1"> </font></p> </div> </div>
	us-gaap	Variable Lease Cost VariableLeaseCost	22672
CY2019Q2	us-gaap	Variable Lease Cost VariableLeaseCost	6659
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4019141

Files In Submission

Name	View Source	Status
0001140361-19-014413-index-headers.html	Edgar Link	pending
0001140361-19-014413-index.html	Edgar Link	pending
0001140361-19-014413.txt	Edgar Link	pending
0001140361-19-014413-xbrl.zip	Edgar Link	pending
ex10_1.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rexn-20190630.xml	Edgar Link	completed
rexn-20190630.xsd	Edgar Link	pending
rexn-20190630_cal.xml	Edgar Link	unprocessable
rexn-20190630_def.xml	Edgar Link	unprocessable
rexn-20190630_lab.xml	Edgar Link	unprocessable
rexn-20190630_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRD
Opus Genetics, Inc. Stock $ird

2019 Q3 Form 10-Q Financial Statement

#000114036119014413 Filed on August 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRD Opus Genetics, Inc. Stock $ird

2019 Q3 Form 10-Q Financial Statement

#000114036119014413 Filed on August 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRD
Opus Genetics, Inc. Stock $ird